The researchers warn that unwarranted long-term use should be
considered a public health concern.
Dementia currently affects about 36 million people worldwide and this
number is expected to double every 20 years, reaching 115 million by 2015.
Although a increased risk of dementia has been identified in benzodiazepine
users, the nature of this association, whether causal or not, remains unclear.
So a team of researchers based in France and Canada set out to
investigate the relationship between the risk of Alzheimer's disease and
benzodiazepine exposure over a several years, as well as a potential
dose-response relationship.
Using data from the Quebec health insurance program database (RAMQ),
they tracked the development of Alzheimer's disease in a sample of elderly
residents living in Quebec, Canada who had been prescribed benzodiazepines.
Over a period of at least six years, they identified 1,796 cases of
Alzheimer's disease. They then compared each case with 7,184 healthy people
matched for age, sex, and duration of follow-up.
Results reported in BMJ-British
Medical Journal September 9, 2014 show that past use of benzodiazepines for three months or more
was associated with an increased risk (up to 51%) of Alzheimer's disease. The
strength of association increased with longer exposure and with use of
long-acting benzodiazepines rather than short-acting ones.
Further adjustment for symptoms that might indicate the start of
dementia, such as anxiety, depression or sleep disorders, did not meaningfully
alter the results.
In this large case-control study, benzodiazepine use was associated
with an increased risk of Alzheimer's disease, say the authors. They emphasise
that the nature of the link is still not definitive, but say the stronger
association seen with long-term exposures "reinforces the suspicion of a
possible direct association, even if benzodiazepine use might also be an early
marker of a condition associated with an increased risk of dementia."
Benzodiazepines are "indisputably valuable tools for managing
anxiety disorders and transient insomnia" they write, but warn that
treatments "should be of short duration and not exceed three months."
They conclude that their findings are of "major importance for
public health, especially considering the prevalence and chronicity of
benzodiazepine use in elderly populations and the high and increasing incidence
of dementia in developed countries."
In view of the evidence, they conclude that "it is now crucial to
encourage physicians to carefully balance the benefits and risks when
initiating or renewing a treatment with benzodiazepines and related products in
elderly patients."
In an accompanying editorial, Professor Kristine Yaffe of the
University of California at San Francisco and Professor Malaz Boustani of the
Indiana University Center for Aging Research, point out that in 2012 the
American Geriatrics Society updated its list of inappropriate drugs for older
adults to include benzodiazepines, precisely because of their unwanted
cognitive side effects.
Yet almost 50% of older adults continue to use these drugs, they say.
And without any formal monitoring system, the potential long term consequences
on brain health are likely to be missed, adding to the growing prevalence of
cognitive impairment among older people, they suggest.
Given
the expanding numbers of older people likely to be treated with several drugs
at a time, and/or who are at risk of Alzheimer's disease, this gap needs to be
plugged, they say.
No comments:
Post a Comment